Science Codex |
Preventing cell death from infection: Scientists demonstrate method to find …
Science Codex LA JOLLA, CA—January 16, 2014—Scientists at The Scripps Research Institute (TSRI) have demonstrated the power of a new drug discovery technique, which allows them to find—relatively quickly and cheaply—antibodies that have a desired effect on cells. |
AbbVie Advances with Cancer Candidate – Analyst BlogNASDAQAbbVie has several pipeline-related events lined up this year including data on multiple sclerosis candidate, daclizumab from the DECIDE study in mid-14 and data on Elagolix from one of the two …
|
FDA to Evaluate Idelalisib for Indolent Non-Hodgkin’s Lymphoma
Monthly Prescribing Reference The NDA submission was supported by a single arm Phase 2 study (Study 101-09) evaluating idelalisib in patients with iNHL that is refractory (non-responsive) to rituximab and to alkylating-agent-containing chemotherapy. Idelalisib is an investigational … FDA Approves Application Review For Refractory Indolent Non-Hodgkin’s …BioResearch Online (press release) |
AbbVie Advances with Cancer CandidateZacks.comAbbVie has several pipeline-related events lined up this year including data on multiple sclerosis candidate, daclizumab from the DECIDE study in mid-14 and data on Elagolix from one of the two pivotal stud…
|
Nomura Reiterates Bullish View on Biogen (BIIB) on Tecfidera Sales
StreetInsider.com (subscription) “We remain focused on daclizumab Phase III MS data in mid-2014 given its $2bn revenue opportunity and anti-LINGO Phase II optic neuritis data in 4Q14, given its read through to the MS trial (2015E). In a year of regulatory and commercial execution, we … |
Pharmacy TimesRheumatoid Arthritis: Walking the WalkPharmacy TimesAccessed December 14, 2013. Rituximab: drug facts and comparisons. Facts & Comparisons database. St. Louis, MO: Wolters Kluwer Health, Inc; March 2005. Accessed December 14, 2013. Me…
|
Teva Pharmaceutical Industries Ltd (ADR) (TEVA): Teva Pharmaceutical …
Seeking Alpha Treanda, used for the treatment of patients with chronic lymphocytic leukemia (CLL) and patients with indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing … |
|
FDA sets standard review for Gilead’s idelalisib in NHL
PMLiVE The marketing application in NHL was filed last September on the back of a single phase II trial in patients whose disease had progressed despite treatment with Roche and Biogen Idec’s Rituxan (rituximab) or conventional chemotherapy. Idelalisib … 3 Reasons to Buy Gilead Sciences, Inc.Motley Fool Standard Review for Gilead’s Oncology Candidate – Analyst BlogNASDAQ Gilead’s Idelalisib NDA accepted by US FDA for the treatment of refractory …MENAFN.COM |
Panel of Six New Anti-Glutamate Receptor Antibodies from AbboMax and Their …PR.com (press release)The neurotransmitter glutamate (Glu) is abundant in the human body, particularly in the nervous system. Glu binds to glutamate receptors (GluRs) leading…
MedscapeRituximab, Abatacept May Interfere With Influenza VaccineMedscapeMost arthritis treatments have no effect on the immunogenicity of adjuvanted pandemic H1N1 influenza (pH1N1) vaccine in patients with rheumatoid arthritis (RA) or spondyloarthropa…